NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $7.19 +0.44 (+6.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.85▼$7.2350-Day Range$6.75▼$12.8852-Week Range$6.71▼$26.35Volume589,817 shsAverage Volume1.12 million shsMarket Capitalization$347.13 millionP/E RatioN/ADividend YieldN/APrice Target$34.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside379.1% Upside$34.44 Price TargetShort InterestBearish15.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector850th out of 936 stocksBiological Products, Except Diagnostic Industry143rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 3 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.56% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Cabaletta Bio has recently increased by 4.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 1.5 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.07) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesJuly 26 at 1:31 AM | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) and Opthea (NASDAQ:OPT) Head to Head ContrastJuly 25 at 7:13 AM | msn.comIASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 8, 2024 | insidermonkey.comCabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?July 2, 2024 | globenewswire.comCabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy ForumJune 14, 2024 | globenewswire.comCabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201May 29, 2024 | finance.yahoo.comCabaletta Bio to Participate in the Jefferies Global Healthcare ConferenceMay 16, 2024 | msn.comCabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future InnovationsJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 15, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)May 15, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024May 15, 2024 | finance.yahoo.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | msn.comCabaletta Bio to Present at H.C. Wainwright BioConnect Investor ConferenceMay 13, 2024 | globenewswire.comCabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | msn.comRetinopathy With Long-Term HCQ Use: Large Study IDs Risk FactorsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial with Promising Therapeutic PotentialApril 27, 2024 | investing.comCabaletta Bio Inc (CABA)See More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Target$34.44 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+379.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.77% Return on Assets-36.09% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.51 per share Price / Book1.30Miscellaneous Outstanding Shares48,280,000Free Float43,507,000Market Cap$347.13 million OptionableOptionable Beta2.42 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $1.02MDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $722.62kDr. David J. Chang FACR (Age 61)M.D., M.P.H., Chief Medical Officer Comp: $721.85kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKRelay TherapeuticsNASDAQ:RLAYCullinan TherapeuticsNASDAQ:CGEMAutolus TherapeuticsNASDAQ:AUTLImmaticsNASDAQ:IMTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 44,156 shares on 7/26/2024Ownership: 0.394%AlphaCentric Advisors LLCBought 5,000 shares on 7/26/2024Ownership: 0.145%Westwood Holdings Group Inc.Bought 82,228 shares on 6/6/2024Ownership: 0.170%Lynx1 Capital Management LPSold 27,428 shares on 5/30/2024Ownership: 4.314%Teachers Retirement System of The State of KentuckyBought 17,905 shares on 5/28/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA shares have decreased by 68.3% and is now trading at $7.19. View the best growth stocks for 2024 here. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.03. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's top institutional shareholders include Bank of New York Mellon Corp (0.39%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder, Catherine Bollard and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS) and CrowdStrike (CRWD). This page (NASDAQ:CABA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.